Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

Sumitomo Corp and Sojitz on Thursday issued cautious profit forecasts for the current fiscal year as U.S. tariffs threaten global supply chains and increase economic uncertainty. Japan's top trade ...

CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my ...

CVS Health has increased its full-year profit forecast and announced plans to exit the Obamacare health insurance market by 2026. Under CEO David Joyner, the company has implemented cost-cutting ...

CVS Health hiked its 2025 forecast above Wall Street’s expectations after improving Medicare benefits contributed to a better ...

CVS Health reported stronger-than-expected earnings and revenue for the first quarter Thursday, raising its full-year guidance as improvement in its insurance business helped ease investor concerns.

(Reuters) -CVS Health raised its full-year profit forecast on Thursday and said it plans to exit the market for Obamacare health insurance plans in 2026, as it seeks to turn around its fortunes ...

Shares of CVS Health Corporation (CVS) traded 10% higher in pre-market on Thursday after the company reported better-than-expected first-quarter (Q1) earnings and raised its full-year profit guidance.

May 1 (Reuters) - Haleon (HLN.L), opens new tab on Thursday raised its medium-term target for profit growth ... Pharmaceuticalscategory CVS Health raises annual profit forecast as turnaround ...

CVS Health boosts its full-year profit expectations following robust quarterly results, indicating a rebound from last year's struggles. The company attributes its success to cost-cutting measures, ...

(RTTNews) - CVS Health Corp. (CVS) revealed earnings for its first quarter that increased from last year and beat the Street estimates. The company's earnings came in at $1.779 billion, or $1.41 ...

The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per share.